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Human exposure to di(2-ethylhexyl) phtha-
late (DEHP) occurs throughout life. Of par-
ticular concern is the exposure of fetuses,
preterm infants, and babies because the devel-
oping human reproductive system may be
affected when the metabolic pathways of
detoxiﬁcation are immature. DEHP has been
shown to damage the male and female repro-
ductive systems in newborn animals. Animal
studies have shown DEHP to be particularly
harmful to developing fetuses: Adverse effects
in the reproductive system include changes in
the testes, speciﬁcally the Sertoli cell, leading
to reduced fertility and changes in sperm
production in males (Foster et al. 2001; Park
et al. 2002; Poon et al. 1997) and ovarian
dysfunction and decreased hormone produc-
tion in females (Davis et al. 1994; Lovekamp-
Swan and Davis 2003). Respiratory distress
and changes in kidney and liver function have
also been linked to DEHP exposure (Crocker
et al. 1988; Kevy and Jacobson 1982; Latini
2000; Rock et al. 1987; Roth et al. 1988;
Ward et al. 1998).
DEHP derives from a family of chemicals
called phthalates. These chemicals are used to
make polyvinyl chloride (PVC) plastic tubing
soft and ﬂexible. Because DEHP does not bind
to the plastic, it can leach out of the PVC
products. DEHP is widely used in PVC dis-
posable medical devices. As in other products,
DEHP can leach out of ﬂexible PVC medical
devices into the solution or medication it
contains and subsequently into the patient
(Rubin and Schiffer 1976).
Species differences in toxicity and metabo-
lism of DEHP have created considerable
debate about the relevance of studies in
rodents to human health. However, exposures
in neonatal intensive care units (NICUs) are
potentially at or above levels known to cause
adverse health effects in relevant animal studies
(e.g., Tickner et al. 2001). For infants requir-
ing intensive care, DEHP exposure can occur
at three orders of magnitude greater than aver-
age adult exposures and at or above levels
shown to cause adverse reproductive effects in
animals (e.g., Tickner et al. 2001).
DEHP concentrations in blood and blood
products are of particular concern for neonates
who receive regular blood transfusions. The
most commonly used blood products—packed
red blood cells and plasma—are typically
stored in DEHP plasticized bags and adminis-
tered to patients through DEHP plasticized
intravenous tubes. Less common treatments
that involve potentially high DEHP exposures
are blood exchange transfusions and extra-
corporeal membrane oxygenation (ECMO).
Although potential exposure to DEHP in
ECMO patients is signiﬁcant, it has not been
associated with short-term toxicity. To evalu-
ate long-term toxicity, we undertook a study of
adolescents who had previously undergone
ECMO treatment in the neonatal period
to assess their onset of puberty and sexual
maturation in comparison to an age- and sex-
matched reference population.
Methods
This prospective study was approved by the
institutional review board at Children’s
National Medical Center. After obtaining
informed consent and assent, we evaluated 19
(13 male and 6 female) adolescents 14–16
years of age who had undergone ECMO as
neonates. All subjects had a complete physical
examination including measurements for
height, weight, head circumference, and
pubertal staging according to the method of
Tanner (Morris and Udry 1980; Tanner
1975). In addition, the testicular volume and
the phallic length were measured in all male
participants. Laboratory tests included meas-
urements of thyroid function [thyroid-stimu-
lating hormone, free thyroxine (T4) by
dialysis, and T4], liver function (aspartate
aminotransferase, alanine aminotransferase,
γ-glutamyl transpeptidase, and total and
direct bilirubin), renal function (blood urea
nitrogen and creatinine), as well as measure-
ments of luteinizing hormone (LH), follicle-
stimulating hormone (FSH), testosterone for
males, and estradiol for females.
Results
Except for one female participant with a diag-
nosis of Marfan syndrome, the rest had normal
growth percentiles for age and sex. All the par-
ticipants had normal laboratory values for thy-
roid, liver, and renal functions. The levels of
LH, FSH, testosterone in males, and estradiol
in females were normal and appropriate for the
degree of pubertal development. Results of the
sex hormones related to pubertal maturation
are shown in Tables 1 and 2 as mean values
(normal ranges).
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Di(2-ethylhexyl) phthalate (DEHP) is used to make polyvinyl chloride (PVC) plastic tubing soft
and ﬂexible. Animal data show that adverse effects of DEHP exposure may include reduced fertil-
ity, reduced sperm production in males, and ovarian dysfunction in females. Known treatments
that involve high DEHP exposures are blood exchange transfusions, extracorporeal membrane
oxygenation (ECMO), and cardiovascular surgery. Although potential exposure to DEHP in
ECMO patients is signiﬁcant, the exposure has not been associated with short-term toxicity. To
evaluate long-term toxicity, we undertook a study of neonatal ECMO survivors to assess their
onset of puberty and sexual maturity. We evaluated 13 male and 6 female subjects at 14–16 years
of age who had undergone ECMO as neonates. All subjects had a complete physical examination
including measurements for height, weight, head circumference, and pubertal assessment by
Tanner staging. The testicular volume and the phallic length were measured in male participants.
Laboratory tests included thyroid, liver, and renal function as well as measurements of luteinizing
hormone, follicle-stimulating hormone, testosterone for males, and estradiol for females. Except
for one patient with Marfan syndrome, the rest had normal growth percentile for age and sex.
All had normal values for thyroid, liver, and renal functions. Sexual hormones were appropriate
for the stage of pubertal maturity. Our results indicate that adolescents exposed to significant
quantities of DEHP as neonates showed no significant adverse effects on their physical growth
and pubertal maturity. Thyroid, liver, renal, and male and female gonadal functions tested were
within normal range for age and sex distribution. Key Words: DEHP, ECMO, toxicity. Environ
Health Perspect 112:1339–1340 (2004). doi:10.1289/ehp.6901 available via http://dx.doi.org/
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Discussion
Our study did not show long-term adverse
outcome related to physical growth and
pubertal development in adolescents previ-
ously exposed to DEHP in the neonatal
period. This is in contrast to the animal data
in multiple species, which show a variety of
reproductive and developmental toxicities
when this plasticizer is administered both
orally and parenterally.
Individuals who have among the highest
exposures to DEHP are those undergoing
medical treatments or procedures such as dialy-
sis, exchange transfusion, ECMO, and cardio-
vascular surgery. Shneider et al. (1989) have
shown that babies undergoing ECMO, in
which the blood is circulating through PVC
tubing, are exposed to 42–140 mg DEHP/kg
body weight over a treatment period of 3–10
days (Shneider et al. 1989). Karle et al. (1997)
reported a lower level of exposure that ranged
from nondetectable to 34.9 mg/kg/treatment
period. The nondetectable level resulted from
the use of a heparin coating on the DEHP-
plasticized PVC circuit. In addition to the
heparin coated tubing, Karle et al. (1997)
attributed the difference between their study
and that of Shneider et al. (1989) to the
smaller surface area of the newer ECMO con-
figurations and the varying percentage of
DEHP composition in each type of tubing.
Although intravenous exposure to DEHP
through the ECMO circuit or other intra-
venous routes exceeds recommended oral
exposure limits, it is difﬁcult to directly com-
pare the two because one is an assumed life-
time daily oral exposure and the other an
acute temporary exposure during ECMO
therapy. Also, the routes of exposure differ:
oral versus intravenous (Doull et al. 1999).
Because the human exposure can be similar to
the doses that are toxic in rodents, there is an
ongoing concern that exposure to DEHP in
neonatal intensive care units may adversely
affect the developing reproductive organs in
these infants (Huber et al. 1996). The most
sensitive system appears to be the immature
male reproductive tract, especially the Sertoli
cell (Parks et al. 2000; Poon et al. 1997).
When DEHP enters the human body, the
compound is metabolized into various sub-
stances that are more rapidly excreted. The
most important of these metabolites, mono-
ethylhexyl phthalate (MEHP) is thought to be
responsible for much of DEHP’s toxicity. The
enzymes that break down DEHP into MEHP
are found mainly in the intestines but also
occur in the liver, kidney, lungs, pancreas, and
plasma. Because conversion of DEHP to
MEHP occurs primarily in the intestinal tract,
exposure to DEHP by ingestion may be more
hazardous than by intravenous exposure,
which largely bypasses the intestinal tract
(Huber et al. 1996; Lewandowski et al. 1980;
Thomas et al. 1979).
Our study of adolescents exposed to signiﬁ-
cant quantities of DEHP as neonates showed
no significant adverse effects of DEHP on
their physical growth and pubertal maturity.
Thyroid, liver, renal, and male and female
gonadal functions tested were within normal
range for age and sex distribution. We hypothe-
size that the acute and short-term exposure to
DEHP in an intravenous form and lack of sig-
niﬁcant conversion of DEHP to MEHP may
be protective against its long-term side effects.
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Table 1. Results of sexual hormones in female subjects matched for Tanner stage [mean value (normal
reference range)].
Females (n) Tanner stage LH (IU/L) FSH (IU/L) Estradiol (pg/mL)
44 6.05 (0.72–15.01) 4.58 (1.26–7.37) 48.75 (25–345)
25 3.7 (0.30–29.38) 2.65 (1.02–9.24) 118.5 (25–410)
Table 2. Results of sexual hormones, testicular volume, and phallic length in male subjects matched for
Tanner stage [mean value (normal reference range)].
Tanner Testosterone Testicular Phallic length
Males (n) stage LH (IU/L) FSH (IU/L) (ng/dL) volume (mL) (cm)
4 2–3 1.83 (0.26–3.74) 2.40 (0.72–10.37) 119 (15–280) 11 (5–10) 8.0 (6.3–8.6)
9 4–5 3.02 (0.55–7.00) 3.61 (1.70–7.00) 387 (105–800) 22 (20–29) 11.2 (8.6–9.9)